Gilead CEO Martin to Step Down, Will Be Replaced by COOBy
Martin presided over strategy to acquire, develop hep C drug
Under Martin, company went from tiny biotech to giant
Gilead Sciences Inc. Chief Executive Officer John Martin, under whom the company developed one of the fastest-selling drugs of all time, will step down and be replaced by Chief Operating Officer John Milligan.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.